Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)
Phase 1
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Primary Liver Cancer
Both
Primary Liver Cancer
Trial Information
Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)
Inclusion Criteria
Inclusion Criteria :
- Male and female are eligible
->18years of age.No upper age limit.
- not pregnant or breastfeeding
- capable of understanding the study goals and protocol and to sign the informed
consent.
- Patients are diagnosed with primary liver cancer and referred for treatment with
biologicals such as Sorafenib or treatment with radionuclides.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
To evaluate the efficacy of PET-imaging versus classic response assessment (MRI, CT-scam) in patients with inoperable liver cancer
Outcome Time Frame:
6 months after start of treatment
Safety Issue:
No
Principal Investigator
Bieke Lambert, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University Hospital, Ghent
Authority:
Belgium: Federal Agency for Medicinal Products and Health Products
Study ID:
2010/115
NCT ID:
NCT01116804
Start Date:
May 2010
Completion Date:
October 2013
Related Keywords:
- Primary Liver Cancer
- Primary liver cancer
- Carcinoma
- Liver Neoplasms
- Carcinoma, Hepatocellular
Name | Location |
|---|
